Shandong Xinhua Secures Key Drug Approval
Company Announcements

Shandong Xinhua Secures Key Drug Approval

Shandong Xinhua Pharmaceutical Company Limited Class H (HK:0719) has released an update.

Shandong Xinhua Pharmaceutical Company Limited announced the successful approval of their Supplementary Drug Application for diazepam tablets by the National Medical Products Administration. This milestone approval allows the transfer of marketing authorization for the product, which follows a technology transfer contract with Jilin Xianfeng Technology Pharmaceutical Co., Ltd. The company confirms the accuracy and completeness of the announcement without any false or misleading statements.

For further insights into HK:0719 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharma Secures Key Drug Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua’s Generic Drug Receives Key Approval
TipRanks HongKong Auto-Generated NewsdeskShandong Xinhua Pharmaceutical Gains Approval for Pentazocine
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App